Brief Summary
Okay, so this video by Dr. Akash Maity is all about the recent updates in PSM, Pharmacology, and OBG that are important for the upcoming INIC exam. He talks about new portals, vaccines, drug approvals, and changes in terminology. The main takeaway is to quickly go through these updates so that you can recall them during the exam.
- Jani portal launched for maternal and child health tracking.
- New drugs approved for various conditions like breast cancer, motion sickness, and HIV.
- PCO is now POS, and TORCH is now SCORCH.
PSM Updates: Jani Portal, Census Mascots, and More
The video starts with updates in PSM. The Jani portal, launched on 7th May 2026, is a digital platform for antenatal, natal, and postnatal care. It's like an upgraded RCH portal that keeps digital health records of women during their reproductive age, tracking maternal and child health services. Then there's the Census 2007 mascot, Vikash (male) and Pragati (female), representing gender equality and promoting people's participation. Also mentioned are CMMS portal (Census Management and Monitoring System), mana framework for AI, Sahi strategy for AI in healthcare, and the Eat Right Movement with its three pillars: safety, healthy, and sustainable. The World Health Day 2026 theme is "Together for Health, Stand with Science."
Vaccines and TB Regimen Updates
Next, Dr. Akash talks about the indigenous vaccine for malaria, Adalivax, and a new vaccine for dengue, Qenga, which has been recently approved. He also mentions the WHO's shorter TB regimen for drug-sensitive TB, which is a 4-month regimen (2HMPZ + 2HPM). This regimen isn't yet adopted in India, and the eligibility criteria include a weight of more than 40 kg and an age of 12 years or more. Mission Sampoorna Suraksha now follows a 95-95-99 approach. DAM is the malaria control program in tribal areas, and Hati is the malaria elimination initiative.
Pharmacology: Recently Approved Drugs
Moving on to pharmacology, Dr. Akash lists recently approved drugs. These include:
- Bestran: For HER2-positive, HR-negative breast cancer.
- Tradipitant: An NK1 inhibitor for motion sickness prevention.
- Brimonidine Tartrate and Carbachol Ophthalmic Solution: For presbyopia in adults.
- Sufentanil: A sodium channel blocker for acute pain.
- Fitusiran: An antithrombin-directed siRNA for hemophilia A or B prophylaxis.
- Nipocalimab: A neonatal Fc receptor blocker for generalized myasthenia gravis.
- Lenacapavir: An HIV-1 capsid protein inhibitor for pre-exposure prophylaxis in HIV-1.
- Brenzocimab: A dipeptidyl peptidase-1 inhibitor for bronchiectasis (non-cystic fibrosis bronchiectasis).
- Mitapivat: A pyruvate kinase inhibitor for adults with alpha or beta thalassemia.
- Roflumilast: A PDE4 inhibitor for idiopathic pulmonary fibrosis.
- Copper Histidinate: A copper replacement therapy for Menkes disease.
- Resmetirom: A thyroid receptor beta agonist for MASH (metabolic dysfunction-associated steatohepatitis), formerly known as NASH.
- Baricitinib: A JAK inhibitor for alopecia areata.
- Tirzepatide: A dual GLP-1 and GIP receptor agonist for obstructive sleep apnea.
- Nafithromycin: A fourth-generation macrolide for hospital-acquired pneumonia.
- Vonoprazan: A novel potassium-competitive acid blocker for GERD and H. pylori infection.
- Cefepime and Enmetazobactam Combination: For complicated UTIs.
- Insulin Icodec: A once-weekly basal insulin analog.
- Orforglipron: An oral GLP-1 agonist approved for obesity.
- Navitide and Buroseritide: C-type natriuretic peptide inhibitor of FGF23, approved for achondroplasia.
- Paltusotine: An oral somatostatin receptor type 2 agonist for acromegaly.
- Atrimod Nasal Spray: A calcium channel blocker for paroxysmal supraventricular tachycardia (PSVT).
- Aficamten and Mavacamten: Myosin inhibitors and calcium sensitizers for hypertrophic obstructive cardiomyopathy as a second-line drug.
- Lecanemab: A PCSK9 inhibitor for hypercholesterolemia.
- Depatuxizumab Mafodotin: An IL-5 inhibitor for severe eosinophilic asthma, the longest-acting monoclonal antibody for asthma.
- Roflumilast: A PDE4 inhibitor for atopic dermatitis.
- Linerixibat: An ileal bile acid transporter inhibitor for cholestatic pruritus associated with primary biliary cholangitis.
- Zoliflodacin and Gepotidacin: Zoliflodacin is a topoisomerase II inhibitor, and Gepotidacin inhibits topoisomerase IV and DNA gyrase; both are approved for gonorrhea.
- Vimkinruca Vaccine: Approved for chickenpox.
- Nirsevimab: Approved for prophylaxis against RSV virus.
- Elenotan and Fasolinetant: Elenotan is an NK1 and NK3 receptor inhibitor, and Fasolinetant is an NK3 receptor inhibitor; both are approved for post-menopausal hot flashes.
- Aceclidine: A cholinergic analog approved for presbyopia.
- Imlunestrant: A selective estrogen receptor downregulator approved for breast cancer with ESR1 mutation.
- Aprocitentan: An endothelin receptor antagonist for systemic hypertension.
- Subpidonium: An anticholinergic analog for axillary hyperhidrosis as a topical application.
- Xanomeline: An M1/M4 agonist approved for psychosis.
- Landiolol: A shortest-acting beta-blocker approved for acute rate control in atrial fibrillation.
- Lecanemab: A humanized IgG1 monoclonal antibody that binds to amyloid-beta soluble protofibrils, approved for early-onset Alzheimer's disease.
- Paloptasogen Roxaparvovec: An adeno-associated virus vector-based gene therapy approved for severe hemophilia A.
OBG Updates: POS and SCORCH
Finally, in OBG, PCO (Polycystic Ovary Syndrome) is now known as POS (Polyendocrine Metabolic Ovarian Syndrome). Also, TORCH infection is now SCORCH (Syphilis, CMV, Others, Rubella, Chickenpox, and HSV). Dr. Akash advises to just go through these updates once before the exam so the names can strike in your mind.
